Trilaciclib is a kinase inhibitor - an enzyme that promotes cell growth. Trilaciclib is not a cancer medicine but a supportive care medicine. Trilaciclib is used to reduce bone marrow suppression and is indicated to reduce the incidence of chemotherapy-induced myelosuppression in adult patients who have previously received platinum- or topotecan-containing regimens in the treatment of cancer. small cell lung.